If you are interested in learning whether you are a good candidate for regenerative procedures from Catalyst Pain Solutions, please complete the Candidate Form below or call us at
1-844-Regenexx (734-3639).

hipx-ray-e1455744460317 Regenexx Hip Stem Cell Therapy

At Catalyst Pain Solutions, our Regenerative stem cell procedures begin when the doctor takes some blood from a vein in your arm. These samples are then sent to the lab, which is part of our medical practice. Your cells are processed and then re-injected into the area in need of repair using imaging guidance (real time fluoroscopy or musculoskeletal ultrasound, using your MRI to plan the injection). They can either be processed the same day (U.S.) or cultured over a two-week span to get more cells (culturing only available through a company that has licensed the procedure for use at a Cayman Islands facility).

For the same day procedure, our trained staff uses our advanced clean room lab to isolate the mesenchymal stem cells sample. These cells are then injected back into the injured area on the same day, with natural growth factors found in your blood platelets. The goal is to deliver much greater numbers of stem cells to the injured area than your body would deliver on its own. For more detail about the procedure, see the Frequently Asked Questions (FAQ’s).

What makes Catalyst Pain Solutions’ Regenerative Stem Cell Procedures different than other same-day stem cell procedures being offered? First, we don’t use a one size fits all centrifuge to prepare cells, we use a sophisticated lab that is part of our medical practice. Second, while some practices add platelet rich plasma to their stem cell concentrate, we use a proprietary “super platelet” mix. The birth of this “super platelet” mix was a series of lab experiments we ran in 2009. By mixing lab prepared PRP (slow release growth factors) and platelet lysate (immediately available growth factors), we were able to get adult stem cells to grow many times more than just PRP or platelet lysate alone.

Are You a Good Candidate for Catalyst Pain Solutions Regenerative Procedures?

If you’re interested in learning whether you are a good candidate for regenerative procedures from Catalyst Pain Solutions please complete the Catalyst Pain Solutions Regenerative Procedure Candidate Form below or call us at 844-Regenexx (734-3639). Regenexx is only offered at our Phoenix facility. We will typically contact you within 24-48 hours of receiving your initial information.

Catalyst Pain Solutions Regenerative Procedure Candidate Form


Address

Problem Area*

Gender*

MaleFemale

How Did You Hear About Us?*

Please Confirm You Are Human

Hip Conditions Commonly Treated with Stem Cell & Platelet Procedures

The list below represents the most commonly treated hip conditions using Regenerative Stem Cell or Platelet Procedures.

This is not a complete list, so please contact us or complete the Candidate Form if you have questions about whether you or your condition can be treated with these non-surgical procedures. The type of procedure used (stem cell or blood platelet) to treat these conditions is largely dependent upon the severity of the injury or condition.

  • Avascular Necrosis
  • Osteonecrosis
  • Bursitis
  • ArthritisTendinopathy
  • Labral / labrum tear

2013 Regenerative Hip Patient Outcome Data

Hip Patient Outcome Data

This data looks at patient outcomes for same-day stem cell treatments for hip arthritis.

Efficacy and Safety of Bone Marrow Concentrate for Osteoarthritis of the Hip; Treatment Registry Results for 196 Patients

Introduction: We investigated the efficacy and safety of autologous bone marrow concentrate (BMC) for the treatment of symptomatic hip osteoarthritis.

Methods: Treatment registry data for 216 hips treated among 196 patients who underwent a BMC procedure for hip osteoarthritis (OA) were analyzed. Data regarding adverse events (AEs), subjective percentage improvement, Oxford Hip Scores (OHS), and numeric pain scale (NPS) scores were assessed and compared to baseline at 1, 3, 6 months, and annually after treatment.

Results: The mean reported subjective percentage improvement across all 216 treated hips was 30.2%. The mean OHS change was 6.4 points improved (p<0.001). The NPS scores from baseline to post treatment decreased from 4.5 to 3.3 (p<0.001). Twelve AEs were reported, none of which were serious or persisting. Patients ≤ 55 years old were substantially more likely to report improvement on the OHS [OR: 11.1 (1.6-77.8)] and also more likely to report greater than 50% improvement on the subjective percentage improvement scale [OR: 2.8 (1.2-6.7)].

Conclusion: The present study of BMC injections for hip OA demonstrated encouraging results for improved outcomes with no significant complications. We found that patients younger than 55 years old were more likely to report improvement on the OHS and subjective percentage improvement scales. Further study with randomized trials is warranted to confirm the reported results.

*Catalyst Pain Solutions, formerly AZ Pain Centers

547302232_640 Regenexx Hip Stem Cell Therapy
hqdefault Regenexx Hip Stem Cell Therapy